BIOCRYST PHARMACEUTICALS INC - 10-Q Filing

Biocryst Pharmaceuticals reports Q3 2026 results including Birmingham facility closure costs and asset impairments.

SEC EDGAR ·

Tickers: $BCRX

Read the full article at SEC EDGAR

More Regulatory news